As described earlier, EphA2 has a clear impact on NSCLC signaling and influences targeted treatment responses including those elicited upon EGFR-TKI treatment or when targeting VEGFR2 expression on tumor cells [27,28,30,31,34,46]. This evidence concerns the gene KDR and non-small cell lung carcinoma.